Royal Bank of Canada
BBOT

Royal Bank of Canada’s BridgeBio Oncology BBOT Stock Holding History

Royal Bank of Canada’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
+154
New +$1.65K ﹤0.01% 6981
2025
Q4 		– Sell
-16
Closed – – 7724
2025
Q3 		$0 Buy
+16
New +$167 ﹤0.01% 7592

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada's BBOT Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 154 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #6981 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in BBOT as recently as Q3 2025.

Royal Bank of Canada first reported a position in BBOT in Q3 2025 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Royal Bank of Canada held 154 shares of BridgeBio Oncology worth $1K as of Q1 2026.
  • BridgeBio Oncology was a new Royal Bank of Canada position in Q1 2026.
  • BridgeBio Oncology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6981 holding.
  • Royal Bank of Canada first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.